ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,675.29
1.08%
US Tech 100
19,136.00
-0.52%
다우존스 지수
41,964.63
0.92%
Bitcoin
85,340.01
-1.79%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Allogene Therapeutics Inc (ALLO) 시세

Allogene Therapeutics Inc

Allogene Therapeutics Inc (ALLO)

NASDAQ
1.69
0.00
(0.00%)
마감 20 3월 5:00AM
15분 지연
1.67
-0.02
( -1.18% )
시간외 단일가: 8:00PM
15분 지연

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

프리미엄

주요 통계 및 세부정보

가격
1.67
매수가
1.55
매도가
1.67
거래량
2,081
0.00 일간 변동폭 0.00
1.32 52주 범위 4.63
market_cap
362.832M
전일 종가
1.69
개장가
-
최근 거래 시간
58
@
1.67
마지막 거래 시간
19:25:35
재정 규모
-
VWAP
-
평균 볼륨(3m)
5,531,539
발행 주식
217,264,738
배당수익률
-
주가수익률
-1.12
주당순이익(EPS)
-1.51
매출
95k
순이익
-327.27M

Allogene Therapeutics Inc 정보

Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple all... Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies. 더 보기

섹터
Biological Pds,ex Diagnstics
산업
Biological Pds,ex Diagnstics
웹사이트
www.allogene.com
본부
Wilmington, Delaware, USA
설립됨
-
Allogene Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the 나스닥 with ticker ALLO. The last closing price for Allogene Therapeutics was US$1.69. Over the last year, Allogene Therapeutics shares have traded in a share price range of US$ 1.32 to US$ 4.63.

Allogene Therapeutics currently has 217,264,738 shares in issue. The market capitalisation of Allogene Therapeutics is US$367.18 million. Allogene Therapeutics has a price to earnings ratio (PE ratio) of -1.12.

ALLO 최신 뉴스

추가 뉴스

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
19 3월 2025
ALLO (0.00%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
15 3월 2025
ALLO (0.00%)

Form S-8 - Securities to be offered to employees in employee benefit plans
Edgar (US Regulatory)
14 3월 2025
ALLO (0.00%)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Edgar (US Regulatory)
14 3월 2025
ALLO (0.00%)

Form 8-K - Current report
Edgar (US Regulatory)
14 3월 2025
ALLO (0.00%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
06 3월 2025
ALLO (0.00%)

Form 3 - Initial statement of beneficial ownership of securities
Edgar (US Regulatory)
05 3월 2025
ALLO (0.00%)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.37-18.1372549022.042.11.5338902431.80899003CS
4-0.88-34.50980392162.552.59911.5337624771.98983149CS
12-0.39-18.9320388352.063.781.3255315392.22234082CS
26-1.19-41.60839160842.863.781.3237507672.31132004CS
52-2.72-61.95899772214.394.631.3230374932.5217389CS
156-7.88-82.51308900529.5517.491.3224416954.87827607CS
260-18.91-91.885325558820.58551.3219220989.78611959CS

ALLO - Frequently Asked Questions (FAQ)

What is the current Allogene Therapeutics share price?
The current share price of Allogene Therapeutics is US$ 1.67
How many Allogene Therapeutics shares are in issue?
Allogene Therapeutics has 217,264,738 shares in issue
What is the market cap of Allogene Therapeutics?
The market capitalisation of Allogene Therapeutics is USD 367.18M
What is the 1 year trading range for Allogene Therapeutics share price?
Allogene Therapeutics has traded in the range of US$ 1.32 to US$ 4.63 during the past year
What is the PE ratio of Allogene Therapeutics?
The price to earnings ratio of Allogene Therapeutics is -1.12
What is the cash to sales ratio of Allogene Therapeutics?
The cash to sales ratio of Allogene Therapeutics is 4.23k
What is the reporting currency for Allogene Therapeutics?
Allogene Therapeutics reports financial results in USD
What is the latest annual turnover for Allogene Therapeutics?
The latest annual turnover of Allogene Therapeutics is USD 95k
What is the latest annual profit for Allogene Therapeutics?
The latest annual profit of Allogene Therapeutics is USD -327.27M
What is the registered address of Allogene Therapeutics?
The registered address for Allogene Therapeutics is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Allogene Therapeutics website address?
The website address for Allogene Therapeutics is www.allogene.com
Which industry sector does Allogene Therapeutics operate in?
Allogene Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
SAGSAG Holdings Ltd
US$ 1.17
(73.33%)
10.42M
OPTNOptiNose Inc
US$ 9.40
(56.67%)
237.19k
LEELee Enterprises Inc
US$ 11.99
(36.72%)
14
IDYAIDEAYA Biosciences Inc
US$ 23.99
(31.74%)
59
IMGCIMG Inc
US$ 0.6146
(28.04%)
7.84M
TRUETrueCar Inc
US$ 0.7234
(-58.43%)
1
CSQCalamos Strategic Total Return Fund
US$ 10.01
(-39.52%)
1
ZCARZoomcar Holdings Inc
US$ 0.2114
(-31.12%)
149.9k
AKBAAkebia Therapeutics Inc
US$ 2.06
(-27.46%)
177.85k
NEHCNew Era Helium Inc
US$ 2.00
(-20.32%)
24
AGMHAGM Group Holdings Inc
US$ 0.0892
(23.89%)
42.5M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 7.91
(-2.83%)
19.16M
BTOGBit Origin Ltd
US$ 0.307
(15.89%)
12.1M
SAGSAG Holdings Ltd
US$ 1.17
(73.33%)
10.41M
IMGCIMG Inc
US$ 0.6146
(28.04%)
7.84M

ALLO Discussion

게시물 보기
glenn1919 glenn1919 4 주 전
ALLO.............................................https://stockcharts.com/h-sc/ui?s=ALLO&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 1 월 전
ALLO...............................https://stockcharts.com/h-sc/ui?s=ALLO&p=W&b=5&g=0&id=p86431144783
👍️0
georgie18 georgie18 2 월 전
ALLO...$2.35...🥳...Nice move off the $1.80 Range Bottom...

georgie18

Member Level
Re: georgie18 post# 387047

Thursday, January 02, 2025 9:51:39 AM

Post#
387852
of 388270
ALLO...$2.20s clearing here...🥳

georgie18

Member Level
Re: georgie18 post# 667756

Monday, December 16, 2024 2:11:12 PM

Post#
667880
of 670030
ALLO...$2.08...🥳...Reversal Candle off the $1.80 range bottom...

georgie18

Member Level
Re: georgie18 post# 385710

Friday, December 13, 2024 2:38:52 PM

Post#
386948
of 387046
ALLO...$1.85...🥳Look like tax selling to me...Scooping up the dip...

georgie18

Member Level
Re: georgie18 post# 664158

Friday, November 15, 2024 11:35:10 AM

Post#
665142
of 667755
ALLO...$2.35...Bottoming out here...🥳They have 400 Million cash reserve...get them through mid 2026...
👍️0
georgie18 georgie18 3 월 전
ALLO...$2.20s clearing here...🥳

georgie18

Member Level
Re: georgie18 post# 667756

Monday, December 16, 2024 2:11:12 PM

Post#
667880
of 670030
ALLO...$2.08...🥳...Reversal Candle off the $1.80 range bottom...

georgie18

Member Level
Re: georgie18 post# 385710

Friday, December 13, 2024 2:38:52 PM

Post#
386948
of 387046
ALLO...$1.85...🥳Look like tax selling to me...Scooping up the dip...

georgie18

Member Level
Re: georgie18 post# 664158

Friday, November 15, 2024 11:35:10 AM

Post#
665142
of 667755
ALLO...$2.35...Bottoming out here...🥳They have 400 Million cash reserve...get them through mid 2026...
👍️0
Monksdream Monksdream 3 월 전
ALLO under $2
👍️0
georgie18 georgie18 3 월 전
ALLO...$2.08...🥳...Reversal Candle off the $1.80 range bottom...

georgie18

Member Level
Re: georgie18 post# 385710

Friday, December 13, 2024 2:38:52 PM

Post#
386948
of 387046
ALLO...$1.85...🥳Look like tax selling to me...Scooping up the dip...

georgie18

Member Level
Re: georgie18 post# 664158

Friday, November 15, 2024 11:35:10 AM

Post#
665142
of 667755
ALLO...$2.35...Bottoming out here...🥳They have 400 Million cash reserve...get them through mid 2026...
👍️0
georgie18 georgie18 3 월 전
ALLO...$1.85...🥳Look like tax selling to me...Scooping up the dip...

georgie18

Member Level
Re: georgie18 post# 664158

Friday, November 15, 2024 11:35:10 AM

Post#
665142
of 667755
ALLO...$2.35...Bottoming out here...🥳They have 400 Million cash reserve...get them through mid 2026...
👍️0
georgie18 georgie18 4 월 전
ALLO...$2.35...Bottoming out here...🥳They have 400 Million cash reserve...get them through mid 2026...
👍️0
georgie18 georgie18 4 월 전
Have a Great Weekend Y'all...🥳
👍️0
georgie18 georgie18 4 월 전
ALLO...$3.19...🥳...https://finance.yahoo.com/news/allogene-therapeutics-inc-allo-q3-110724066.html
👍️0
georgie18 georgie18 4 월 전
ALLO...$3.31...Fins after todays close...🥳

georgie18

Member Level
Re: georgie18 post# 385280

Wednesday, November 06, 2024 10:27:01 AM

Post#
385286
of 385334
ALLO...$3.22s clearing here...🥳...Looking for the $5.78 Breakout... https://schrts.co/wITCFkcf

georgie18

Member Level
Re: georgie18 post# 663758

Wednesday, November 06, 2024 10:06:32 AM

Post#
663791
of 663807
ALLO...$3.17...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 385240

Wednesday, November 06, 2024 7:12:20 AM

Post#
385251
of 385279
ALLO...$3.10...🥳

georgie18

Member Level
Re: georgie18 post# 663652

Tuesday, November 05, 2024 3:37:32 PM

Post#
663738
of 663757
ALLO...$3 ...starting up again...🥳

georgie18

Member Level
Re: georgie18 post# 385217

Tuesday, November 05, 2024 9:15:04 AM

Post#
385226
of 385239
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product
Ongoing Phase 1 Data Supported the FDA's Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC Therapies
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.
👍️0
georgie18 georgie18 4 월 전
ALLO...$3.22s clearing here...🥳...Looking for the $5.78 Breakout... https://schrts.co/wITCFkcf

georgie18

Member Level
Re: georgie18 post# 663758

Wednesday, November 06, 2024 10:06:32 AM

Post#
663791
of 663807
ALLO...$3.17...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 385240

Wednesday, November 06, 2024 7:12:20 AM

Post#
385251
of 385279
ALLO...$3.10...🥳

georgie18

Member Level
Re: georgie18 post# 663652

Tuesday, November 05, 2024 3:37:32 PM

Post#
663738
of 663757
ALLO...$3 ...starting up again...🥳

georgie18

Member Level
Re: georgie18 post# 385217

Tuesday, November 05, 2024 9:15:04 AM

Post#
385226
of 385239
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product
Ongoing Phase 1 Data Supported the FDA's Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC Therapies
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.
👍️0
georgie18 georgie18 4 월 전
ALLO...$3.17...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 385240

Wednesday, November 06, 2024 7:12:20 AM

Post#
385251
of 385279
ALLO...$3.10...🥳

georgie18

Member Level
Re: georgie18 post# 663652

Tuesday, November 05, 2024 3:37:32 PM

Post#
663738
of 663757
ALLO...$3 ...starting up again...🥳

georgie18

Member Level
Re: georgie18 post# 385217

Tuesday, November 05, 2024 9:15:04 AM

Post#
385226
of 385239
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product
Ongoing Phase 1 Data Supported the FDA's Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC Therapies
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.
👍️0
georgie18 georgie18 4 월 전
ALLO...$3.10...🥳

georgie18

Member Level
Re: georgie18 post# 663652

Tuesday, November 05, 2024 3:37:32 PM

Post#
663738
of 663757
ALLO...$3 ...starting up again...🥳

georgie18

Member Level
Re: georgie18 post# 385217

Tuesday, November 05, 2024 9:15:04 AM

Post#
385226
of 385239
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product
Ongoing Phase 1 Data Supported the FDA's Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC Therapies
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.
👍️0
georgie18 georgie18 4 월 전
ALLO...$3 ...starting up again...🥳

georgie18

Member Level
Re: georgie18 post# 385217

Tuesday, November 05, 2024 9:15:04 AM

Post#
385226
of 385239
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product
Ongoing Phase 1 Data Supported the FDA's Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC Therapies
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.
👍️0
georgie18 georgie18 4 월 전
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product
Ongoing Phase 1 Data Supported the FDA's Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC Therapies
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.
👍️0
georgie18 georgie18 4 월 전
ALLO...$3...Hitting again...🥳

georgie18

Member Level
Re: None

Wednesday, October 30, 2024 10:54:12 AM

Post#
385056
of 385216
ALLO...$2.93..."W" in play here... https://schrts.co/BrIJNzMB ...Financials will be announced on the 7th of November...28% short...insiders own 34%...Float 138 million...
👍️0
georgie18 georgie18 5 월 전
ALLO...$2.93..."W" in play here... https://schrts.co/BrIJNzMB ...Financials will be announced on the 7th of November...28% short...insiders own 34%...Float 138 million...
👍️0
TrendTrade2016 TrendTrade2016 5 월 전
ALLO BIO BEASTING
👍️0
Monksdream Monksdream 5 월 전
ALLO under $3
👍️0
Mactheriverrat Mactheriverrat 5 월 전
ALLO coiled to run
👍️0
georgie18 georgie18 6 월 전
ALLO...$3 Hitting again...🥳

georgie18

Member Level
Re: georgie18 post# 41

Friday, September 27, 2024 3:57:49 PM

Post#
42
of 42
ALLO...$2.90...Setting up for the $3 Break again...🥳

georgie18

Member Level
Re: georgie18 post# 658272

Wednesday, September 25, 2024 10:03:06 AM

Post#
659219
of 659662
ALLO...$2.65...added more here on the dip...🥳

georgie18

Member Level
Re: None

Wednesday, September 18, 2024 1:30:50 PM

Post#
40
of 40
ALLO...$2.79 added the dip ...🥳
👍️0
georgie18 georgie18 6 월 전
ALLO...$2.90...Setting up for the $3 Break again...🥳

georgie18

Member Level
Re: georgie18 post# 658272

Wednesday, September 25, 2024 10:03:06 AM

Post#
659219
of 659662
ALLO...$2.65...added more here on the dip...🥳

georgie18

Member Level
Re: None

Wednesday, September 18, 2024 1:30:50 PM

Post#
40
of 40
ALLO...$2.79 added the dip ...🥳
👍️0
georgie18 georgie18 6 월 전
ALLO...$2.65...added more here on the dip...🥳

georgie18

Member Level
Re: None

Wednesday, September 18, 2024 1:30:50 PM

Post#
40
of 40
ALLO...$2.79 added the dip ...🥳
👍️0
georgie18 georgie18 6 월 전
ALLO...$2.79 added the dip ...🥳
👍️0
georgie18 georgie18 6 월 전
ALLO...$2.98...W pattern still in play here...Looking for $3.23 Break...🥳off the $2.55 alert...

georgie18

Member Level
Re: georgie18 post# 36

Wednesday, September 11, 2024 4:02:04 PM

Post#
38
of 38
ALLO...$2.92...Psar flipped Bullish...Trying for upper bollie break...🥳...

georgie18

Member Level
Re: georgie18 post# 652456

Monday, August 26, 2024 2:22:57 PM

Post#
655267
of 657175
ALLO...$2.79...Off my $2.55...Alert...Still looking for $3 Break...🥳

georgie18

Member Level
Re: georgie18 post# 32

Thursday, August 22, 2024 9:38:16 AM

Post#
33
of 35
ALLO...$2.72s clearing here...🥳

georgie18

Member Level
Re: georgie18 post# 652456

Monday, August 19, 2024 3:08:16 PM

Post#
654171
of 654707
ALLO...$2.60s clearing here...🥳

georgie18

Member Level
Re: None

Tuesday, August 06, 2024 1:20:27 PM

Post#
382404
of 382735
ALLO...$2.55s starting here...coming off the bottom...🥳
👍️0
georgie18 georgie18 6 월 전
ALLO...$2.92...Psar flipped Bullish...Trying for upper bollie break...🥳...

georgie18

Member Level
Re: georgie18 post# 652456

Monday, August 26, 2024 2:22:57 PM

Post#
655267
of 657175
ALLO...$2.79...Off my $2.55...Alert...Still looking for $3 Break...🥳

georgie18

Member Level
Re: georgie18 post# 32

Thursday, August 22, 2024 9:38:16 AM

Post#
33
of 35
ALLO...$2.72s clearing here...🥳

georgie18

Member Level
Re: georgie18 post# 652456

Monday, August 19, 2024 3:08:16 PM

Post#
654171
of 654707
ALLO...$2.60s clearing here...🥳

georgie18

Member Level
Re: None

Tuesday, August 06, 2024 1:20:27 PM

Post#
382404
of 382735
ALLO...$2.55s starting here...coming off the bottom...🥳
👍️0
Monksdream Monksdream 7 월 전
ALLO under $3

👍️0
georgie18 georgie18 7 월 전
ALLO...$2.79...Off my $2.55...Alert...Still looking for $3 Break...🥳

georgie18

Member Level
Re: georgie18 post# 32

Thursday, August 22, 2024 9:38:16 AM

Post#
33
of 35
ALLO...$2.72s clearing here...🥳

georgie18

Member Level
Re: georgie18 post# 652456

Monday, August 19, 2024 3:08:16 PM

Post#
654171
of 654707
ALLO...$2.60s clearing here...🥳

georgie18

Member Level
Re: None

Tuesday, August 06, 2024 1:20:27 PM

Post#
382404
of 382735
ALLO...$2.55s starting here...coming off the bottom...🥳
👍️0
georgie18 georgie18 7 월 전
Thanks for posting...🥳
👍️0
glens0 glens0 7 월 전
ALLO Current Institutional Ownership Percentage 83.63% up from 63%
187 Institutional Holders 165,517,865 Total Shares Held
https://www.marketbeat.com/stocks/NASDAQ/ALLO/institutional-ownership/
👍️0
georgie18 georgie18 7 월 전
ALLO...$2.72s clearing here...🥳

georgie18

Member Level
Re: georgie18 post# 652456

Monday, August 19, 2024 3:08:16 PM

Post#
654171
of 654707
ALLO...$2.60s clearing here...🥳

georgie18

Member Level
Re: None

Tuesday, August 06, 2024 1:20:27 PM

Post#
382404
of 382735
ALLO...$2.55s starting here...coming off the bottom...🥳
👍️0
georgie18 georgie18 7 월 전
ALLO...$2.60s clearing here...🥳

georgie18

Member Level
Re: None

Tuesday, August 06, 2024 1:20:27 PM

Post#
382404
of 382735
ALLO...$2.55s starting here...coming off the bottom...🥳
👍️0
georgie18 georgie18 7 월 전
ALLO...$2.55s starting here...coming off the bottom...🥳
👍️0
Monksdream Monksdream 8 월 전
ALLO under $3
👍️0
Monksdream Monksdream 10 월 전
ALLO under $3
👍️0
Monksdream Monksdream 11 월 전
ALLO under $3
👍️0
Monksdream Monksdream 1 년 전
ALLO new 52 week low
👍️0
NY1972 NY1972 1 년 전
Yes. Signet-ring, TP53. ... dying. Even more aggressive than the ones enrolled in CART trial
👍️0
jondoeuk jondoeuk 1 년 전
Was that the case study (50-year-old female)?

I know the CAR-T is already in registrational trials both in China and the US. If all goes to plan, they expected to submit an NDA to the NMPA in 2024 and a BLA to the FDA in 2025. A next-gen version is in the clinic as well https://aacrjournals.org/clincancerres/article/26/20/5494/82735/Coexpression-of-IL7-and-CCL21-Increases-Efficacy

Also https://www.biospace.com/article/moderna-carsgen-join-forces-combining-mrna-cancer-vaccine-with-car-t/

However, it's getting pretty crowded
👍️0
NY1972 NY1972 1 년 전
$AFMD 24+ ATEZO was pretty effective (1/1) compared to CARThttps://t.co/WtuFoQNM37— Bon Wood (@ny1972_47) September 28, 2023
👍️0
jondoeuk jondoeuk 1 년 전
Upcoming https://www.globenewswire.com/news-release/2023/09/27/2750477/0/en/Allogene-Therapeutics-Announces-Three-Poster-Presentations-from-its-Next-Generation-AlloCAR-T-Platform-at-the-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting.html
👍️0
dmerc dmerc 2 년 전
short 49% Mentioned by Roensche Capital
👍️0
dmerc dmerc 2 년 전
https://www.benzinga.com/quote/ALLO/analyst-ratings
👍️0
jondoeuk jondoeuk 2 년 전
An oral presentation at AACR next month https://www.abstractsonline.com/pp8/#!/10828/presentation/10251
👍️0
jondoeuk jondoeuk 2 년 전
A proprietary approach to control rejection https://www.globenewswire.com/news-release/2022/11/10/2553356/0/en/Allogene-Therapeutics-Unveils-Novel-Approach-to-Generate-Engineered-AlloCAR-T-Cells-to-Control-Immune-Rejection-at-the-Annual-Meeting-of-the-Society-for-Immunotherapy-of-Cancer.html

This is one of a number of next-gen technologies being pioneered. Others, include https://www.globenewswire.com/en/news-release/2023/02/01/2599947/0/en/Allogene-Therapeutics-Presents-Data-on-Dagger-a-Next-Generation-AlloCAR-T-Platform-Technology.html
👍️0
jondoeuk jondoeuk 2 년 전
R&D showcase PR https://www.globenewswire.com/news-release/2022/11/29/2564467/0/en/Allogene-Therapeutics-R-D-Showcase-Features-Hematologic-and-Solid-Tumor-Advances-Across-its-AlloCAR-T-Platform.html

Slides https://ir.allogene.com/static-files/3eacf8bf-3cd0-47bc-a5ac-f5715083883a
👍️0
jondoeuk jondoeuk 3 년 전
ASGCT PR https://www.globenewswire.com/news-release/2022/05/19/2446950/0/en/Allogene-Therapeutics-Announces-Oral-Presentation-of-Pre-Clinical-Data-Highlighting-Improved-Anti-Tumor-Activity-of-Donor-Derived-Allogeneic-CAR-T-Cells-at-American-Society-of-Gene.html
👍️0
jondoeuk jondoeuk 3 년 전
New preclinical data https://aacrjournals.org/cancerrescommun/article/2/3/158/684708/Allogeneic-Anti-BCMA-CAR-T-Cells-Are-Superior-to
👍️0
jondoeuk jondoeuk 3 년 전
Additional data https://allogene.com/resources/download/ALPHA-Study.pdf https://allogene.com/resources/download/ALPHA2-Study.pdf https://allogene.com/resources/download/UNIVERSAL-Updated-Phase-1-Data-Validates-Feasibility-Allogeneic.pdf
https://ir.allogene.com/static-files/891ef05d-ff61-4c95-9a55-9ff7a515102d
👍️0

최근 히스토리

NASDAQ
ALLO
Allogene Therapeutics
USOTC
ALLIF
Atlantic Lithium (QX)
USOTC
AOIFF
Africa Oil (PK)
USOTC
ASOMY
ASOS (PK)
USOTC
AEGXF
Aecon (PK)
USOTC
ATRRF
Altarea (PK)
NASDAQI
DALI
First Trust DorseyWright...
USOTC
AMKAF
AP Moeller Maers A (PK)
COIN
XENNBTC
XENON
USOTC
LASWS
Landa App (GM)
ASX
BTH
Bigtincan
AQEU
STARBS
Starbreeze AB
NASDAQ
GOCO
GoHealth
NASDAQ
SKGRW
SK Growth Opportunities
USOTC
ALEDY
Allied (PK)
LSE
70YJ
Natwest.m 26 A
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지